Search results for "Gilead Sciences"

Story & Multimedia Results

Sort by Relevance Sort by Date

Analyst Actions: Google, Overstock.com, Gilead Sciences July 18, 2008

PACIFIC CREST CUTS ESTIMATES, TARGET; KEEPS OUTPERFORM ON GOOGLE Pacific Crest analyst Steve Weinstein says Google's (GOOG) $3.90 billion second quarter net revenue ...

Gilead Sciences: High-Performing Pharmaceutical March 26, 2009

Gilead SciencesIndustry: PharmaceuticalsSales: $5.3 billionNet Income: $2 billion In late February 2008, some 40,000 people learned they may have been exposed to ...

BW Online | May 18, 2004 | Friedman Billings Ups Gilead Sciences to Outperform May 18, 2004

Analyst Jim Reddoch says Gilead's HIV drug combination got FDA review priority

BW Online | September 23, 2002 | Morgan Stanley Ups Gilead Sciences Estimates September 23, 2002

Analyst Caroline Copithorne says the FDA's quick approval of Gilead's hepatitis drug is a big win

BW Online | September 16, 2003 | J.P. Morgan Lowers Gilead Sciences to September 16, 2003

After a strong first half, analyst David Molowa thinks it will be tougher for Gilead to beat consensus forecasts going forward

BW Online | June 27, 2003 | J.P. Morgan Keeps 'Overweight' on Gilead Sciences June 27, 2003

Analyst David Molowa thinks Gilead's HIV drug will receive approval by July 3

S&P Picks and Pans: Citigroup, Lowe's, Goldman Sachs, Covidien, Gilead Sciences November 17, 2008

S&P MAINTAINS HOLD RECOMMENDATION ON SHARES OF CITIGROUP (C; 9.25): In an unconfirmed report, Dow Jones reports that the size of Citigroup's proposed, near-term job ...

BW Online | August 7, 2002 | BoA Keeps 'Buy' on Gilead Sciences August 07, 2002

An FDA panel supports the approval of the biotech's new treatment for chronic Hepatitis B

BW Online | August 26, 2004 | First Albany Keeps Buy on Gilead Sciences August 26, 2004

The drugmaker reported positive study results for its HIV drugs

BW Online | July 30, 2004 | Piper Jaffray Ups Gilead Sciences to Outperform July 30, 2004

Analyst Thomas Wei says his upgrade is based on the biotech firm's better fundamental performance

BW Online | June 27, 2003 | Gilead Sciences Climbs June 27, 2003

Esperion Therapeutics jumps; Nike drops; plus more of today's stocks in the news

BW Online | March 27, 2003 | Lehman Ups Gilead Sciences to 'Overweight' March 27, 2003

Analyst Craig Parker sees another quarter of Viread sales above expectations

BW Online | March 7, 2003 | Thomas Weisel Starts Gilead Sciences with 'Buy' March 07, 2003

Analyst Patrick Mooney thinks the biotech can deliver rapid revenue and earnings per share growth over the next three to five years

BW Online | July 2, 2003 | S&P Says Accumulate Gilead Sciences July 02, 2003

Also: analysts' opinions on Constellation Brands and Walgreen. Plus more...

Prudential Upgrades Gilead Sciences to Neutral April 19, 2006

Analyst Ron Ellis ties the company's upside in first-quarter results to strong sales in its HIV franchise and Tamiflu royalties.